Biomea Fusion Shares Surge on Full Enrollment in Phase II Diabetes Trial

Biomea Fusion Inc shares traded sharply higher on Monday following an operational milestone in its lead metabolic drug program.

Here is what investors need to know.

Biomea Fusion stock surged higher. What is behind the BMEA rally?

COVALENT-211 Reaches Full Enrollment, Topline Data Expected in Q1 2027

The clinical-stage biopharmaceutical company announced it has completed patient enrollment in COVALENT-211, a randomized, double-blind, placebo-controlled Phase II trial evaluating its oral menin inhibitor icovamenib.

The trial enrolled 64 participants with insulin-deficient type 2 diabetes who were poorly controlled on a background of standard care. Biomea expects to report 26-week primary endpoint topline data in Q1 2027.

Upcoming Clinical Milestones Focus on Beta-Cell Restoration

Management emphasized that the milestone keeps the broader Phase II diabetes development program on track. Its companion Phase II study COVALENT-212, evaluating icovamenib in T2D patients who failed to reach glycemic targets on GLP-1 therapy, remains ongoing, with enrollment expected to complete by year-end and 26-week topline results anticipated in Q2 2027.

Both trials are based on earlier Phase II data showing that a 12-week course of icovamenib produced durable, placebo-adjusted HbA1c reductions of 1.5% to 1.8%, alongside rising C-peptide levels.

BMEA Stock Rallies Sharply on Monday

Biomea Fusion shares closed up 16.06% on Monday at $1.59.